Jaguar Health advances extension phase of pivotal oral crofelemer trial in pediatric MVID patients

Jaguar Animal Health, Inc.

Jaguar Animal Health, Inc.

JAGX

0.00
  • Jaguar Health highlighted ongoing development of a liquid crofelemer formulation for rare pediatric intestinal-failure disorders, targeting a potential mid-2027 NDA filing.
  • Earlier proof-of-concept results were already presented at NASPGHAN 2025, indicating reduced reliance on parenteral support in initial MVID and SBS-IF patients.
  • New data are set for future presentation via two late-breaking abstracts at ESPGHAN, covering investigator-initiated and expanded-access use in pediatric patients.
  • The company is running an extension phase of its pivotal MVID study, with an active-treatment-only continuation intended to support the planned regulatory submission.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202605281000ACCESSWRNAPR_____1171349) on May 28, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.